Friday - July 4, 2025
IMF Proudly Announces EMA-CHMP Positive Qualification Advice to I2TEAMM Novel Biomarker Procedure Application on Use of MRDnegCR as Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials
July 03, 2025
STUDIO CITY, California, July 3 -- The International Myeloma Foundation issued the following news:

* * *

The IMF Proudly Announces EMA-CHMP Positive Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials

Another Remarkable Milestone for the IMF and i2TEAMM, Following the FDA-ODAC Unanimous 12-0 Vote in April 2024

*< . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products